Comparative Pharmacology
Head-to-head clinical analysis: PENBRITIN S versus PENICILLIN 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENBRITIN S versus PENICILLIN 2.
PENBRITIN-S vs PENICILLIN-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillinase-sensitive penicillin; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly/intravenously every 4-6 hours for moderate to severe infections.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 7-10 hours in anuria).
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
Renal: 75-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: ~10%.
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic